Veru Inc (VERU)

$2.46 0.03 (1.23%)

17:38 EDT VERU Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 131.64M

PE Ratio -8.20

EPS -0.3

Volume (Avg. Vol.) 178,800

Day's Range 2.40 - 2.48

52-Week Range 1.85 - 4.74

Dividend & Yield N/A (N/A)

VERU Stock Predictions, Articles, and Veru Inc News

From InvestorPlace
From the Web

7 Sin Stocks Whose Profits Are Too Irresistible to Pass Up

By Will Ashworth, InvestorPlace Contributor Aug 5, 2020

If you’re able to overlook the shortcomings of these seven sin stocks, your long-term gains will be enough to soothe your conscience.

7 ‘A’-Rated Stocks Under $5 to Buy Now

By Louis Navellier, Editor, Growth Investor Feb 7, 2020

These small-cap stocks to buy are all under $5, but they come from industries and sectors with massive potential.

Veru enrolls in Phase 2 trial for an oral drug for metastatic prostate cancer

From Seeking Alpha Sep 29, 2020

Veru (VERU +2.7%) has fully enrolled its Phase 2 clinical study of VERU-111, its novel, oral, alpha and beta tubulin targeting drug for metastatic castration and novel androgen receptor targeting agent resistant prostate cancer.The study enrolled a total of 40 men at 13 clinical sites in the U.S.Phase 2 clinical trial will evaluate the efficacy and safety of VERU-111 in 40 men with metastatic prostate cancer.Press ReleaseFind more info on the drug in company presentation.

The Exact Trigger that Indicates Volatility in Veru Inc

From Capital Market Laboratories Sep 19, 2020

The Trigger That Turned Veru Inc (NASDAQ:VERU) Volatility into a Winner.

Veru: Q3 Earnings Insights

From Benzinga Aug 13, 2020

Shares of Veru (NASDAQ:VERU) rose 4% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 25.00% year over year to ($0.05),...

Veru Announces ESMO Congress 2020 Oral Presentation of Positive Clinical Results from its VERU-111 Phase 1b Study in Metastatic Prostate Cancer

From BusinessInsider Sep 18, 2020

—Advancing VERU-111 to a Pivotal Phase 3 Clinical Program—MIAMI, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and ur...

The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference

From Benzinga Sep 13, 2020

Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market. The week also witnessed a flurry of...

Insider Buys Veru's Stock

From Benzinga Aug 26, 2020

Veru Inc (NASDAQ:VERU) was trading 3.5% higher from the previous closing price. A Form 4 filing filed with the SEC on Tuesday, August 25 showed that and Greco Michele bought 5,000...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy